Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 131494, 12 pages
http://dx.doi.org/10.1155/2014/131494
Research Article

Glioma-Associated Antigen HEATR1 Induces Functional Cytotoxic T Lymphocytes in Patients with Glioma

1Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
2Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
3Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
4Key Laboratory of Medical Molecular Virology of Ministry of Education/Health at Shanghai Medical College, Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Fudan University, Jinshan District, Shanghai 200040, China
5Department of Immunology and Biotherapy Research Center, Shanghai Medical College, Fudan University, Shanghai 200040, China

Received 8 March 2014; Revised 17 May 2014; Accepted 16 June 2014; Published 9 July 2014

Academic Editor: Bin Zhang

Copyright © 2014 Zhe Bao Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Y. Wen and S. Kesari, “Malignant gliomas in adults,” The New England Journal of Medicine, vol. 359, no. 5, pp. 492–507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. S. Yu, C. J. Wheeler, P. M. Zeltzer et al., “Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration,” Cancer Research, vol. 61, no. 3, pp. 842–847, 2001. View at Google Scholar · View at Scopus
  3. A. B. Heimberger and J. H. Sampson, “Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?” Neuro-Oncology, vol. 13, no. 1, pp. 3–13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. Z. Li, J. Lee, D. Mukherjee et al., “Immunotherapy targeting glioma stem cells—insights and perspectives,” Expert Opinion on Biological Therapy, vol. 12, no. 2, pp. 165–178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. K. Singh, C. Hawkins, I. D. Clarke et al., “Identification of human brain tumour initiating cells,” Nature, vol. 432, no. 7015, pp. 396–401, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. S. K. Singh, I. D. Clarke, M. Terasaki et al., “Identification of a cancer stem cell in human brain tumors,” Cancer Research, vol. 63, no. 18, pp. 5821–5828, 2003. View at Google Scholar · View at Scopus
  7. S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response,” Nature, vol. 444, no. 7120, pp. 756–760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Hambardzumyan, M. Squartro, and E. C. Holland, “Radiation resistance and stem-like cells in brain tumors,” Cancer Cell, vol. 10, no. 6, pp. 454–456, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Murat, E. Migliavacca, T. Gorlia et al., “Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma,” Journal of Clinical Oncology, vol. 26, no. 18, pp. 3015–3024, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Hua, Y. Yao, Y. Chu et al., “The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma,” Journal of Neuro-Oncology, vol. 105, no. 2, pp. 149–157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. Q. Xu, G. Liu, X. Yuan et al., “Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens,” Stem Cells, vol. 27, no. 8, pp. 1734–1740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Ueda, K. Ohkusu-Tsukada, N. Fusaki et al., “Identification of HLA-A2- And A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy,” International Journal of Cancer, vol. 126, no. 4, pp. 919–929, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. E. Brown, R. Starr, C. Martinez et al., “Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells,” Cancer Research, vol. 69, no. 23, pp. 8886–8893, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Pellegatta, P. L. Poliani, D. Corno et al., “Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas,” Cancer Research, vol. 66, no. 21, pp. 10247–10252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. C. E. Brown, R. Starr, B. Aguilar et al., “Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells,” Clinical Cancer Research, vol. 18, no. 8, pp. 2199–2209, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. R. A. Morgan, L. A. Johnson, J. L. Davis et al., “Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.,” Human gene therapy, vol. 23, no. 10, pp. 1043–1053, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Tchoghandjian, N. Baeza, C. Colin et al., “A2B5 cells from human glioblastoma have cancer stem cell properties,” Brain Pathology, vol. 20, no. 1, pp. 211–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. T. Ogden, A. E. Waziri, R. A. Lochhead et al., “Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas,” Neurosurgery, vol. 62, no. 2, pp. 505–515, 2008. View at Publisher · View at Google Scholar
  19. M. Xu, Y. Yao, W. Hua et al., “Mouse glioma immunotherapy mediated by A2B5+GL261 cell lysate-pulsed dendritic cells,” Journal of Neuro-Oncology, vol. 116, pp. 497–504, 2014. View at Google Scholar
  20. M. Bleakley, B. E. Otterud, J. L. Richardt et al., “Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells,” Blood, vol. 115, no. 23, pp. 4923–4933, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Yao, A. K. Chan, Z. Y. Qin et al., “Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival,” PLoS ONE, vol. 8, no. 6, Article ID e67421, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. B. Wu, L. Cai, S. J. Lin et al., “High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance,” Neuro-Oncology, vol. 15, no. 9, pp. 1264–1275, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Okano, W. J. Storkus, W. H. Chambers, I. F. Pollack, and H. Okada, “Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain,” Clinical Cancer Research, vol. 8, pp. 2851–2855, 2002. View at Google Scholar
  24. M. Hatano, J. Eguchi, T. Tatsumi et al., “EphA2 as a glioma-associated antigen: a novel target for glioma vaccines,” Neoplasia, vol. 7, no. 8, pp. 717–722, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Somasundaram, L. Caputo, D. P. Guerry, and D. Herlyn, “CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma,” Journal of Translational Medicine, vol. 3, article 41, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Z. Jian, J. Eguchi, C. A. Kruse et al., “Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics,” Clinical Cancer Research, vol. 13, no. 2, pp. 566–575, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. C. Jia, B. Ni, Z. M. Huang et al., “Identification of two novel HLA-A *0201-restricted CTL epitopes derived from MAGE-A4,” Clinical & Developmental Immunology, vol. 2010, Article ID 567594, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Bredenbeck, F. O. Losch, T. Sharav et al., “Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy,” Journal of Immunology, vol. 174, no. 11, pp. 6716–6724, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Hakamada, K. Funatsuki, H. Morita et al., “Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitopes by ELISpot assay using peptides with human leukocyte antigen-A*2402-binding motifs,” The Journal of General Virology, vol. 85, no. 6, pp. 1521–1531, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. M. L. Shinohara, M. Jansson, E. S. Hwang, M. B. F. Werneck, L. H. Glimcher, and H. Cantor, “T-bet-dependent expression of osteopontin contributes to T cell polarization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 47, pp. 17101–17106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. M. T. Duffour, P. Chaux, C. Lurquin, G. Cornelis, T. Boon, and P. van der Bruggen, “A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes,” European Journal of Immunology, vol. 29, pp. 3329–3337, 1999. View at Google Scholar
  32. B. Liang, L. Zhu, Z. Liang et al., “A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China,” Cellular & Molecular Immunology, vol. 3, no. 6, pp. 453–458, 2006. View at Google Scholar · View at Scopus
  33. M. Azuma, R. Toyama, E. Laver, and I. B. Dawid, “Perturbation of rRNA synthesis in the bap28 mutation leads to apoptosis mediated by p53 in the zebrafish central nervous system,” Journal of Biological Chemistry, vol. 281, no. 19, pp. 13309–13316, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. A. J. Barrett and J. J. Melenhorst, “Minor histocompatibility antigen discovery: turning up the HEATR,” Blood, vol. 115, no. 23, pp. 4630–4631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. C. E. Myers, P. Hanavan, K. Antwi et al., “CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells,” Cancer Immunology, Immunotherapy, vol. 60, no. 9, pp. 1319–1332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Schmitz, A. Temme, V. Senner et al., “Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy,” British Journal of Cancer, vol. 96, no. 8, pp. 1293–1301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Liu, H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu, “HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells,” Cancer Research, vol. 64, no. 14, pp. 4980–4986, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Shimato, A. Natsume, T. Wakabayashi et al., “Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen: laboratory investigation,” Journal of Neurosurgery, vol. 109, no. 1, pp. 117–122, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Kawakami, M. Terabe, M. Kawakami, J. A. Berzofsky, and R. K. Puri, “Characterization of a novel human tumor antigen interleukin-13 receptor α2 chain,” Cancer Research, vol. 66, no. 8, pp. 4434–4442, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. I. O. Sullivan, M. Blaszczyk-Thurin, C. T. Shen, and H. C. J. Ertl, “A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma,” Cancer Gene Therapy, vol. 10, no. 9, pp. 678–688, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Imaizumi, T. Kuramoto, K. Matsunaga et al., “Expression of the tumor-rejection antigen SART1 in brain tumors,” International Journal of Cancer, vol. 83, pp. 760–764, 1999. View at Google Scholar
  42. K. Murayama, T. Kobayashi, T. Imaizumi et al., “Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides,” Journal of Immunotherapy, vol. 23, no. 5, pp. 511–518, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Nonaka, N. Tsuda, S. Shichijo et al., “Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors,” Tissue Antigens, vol. 60, no. 4, pp. 319–327, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Tsuda, Y. Nonaka, S. Shichijo et al., “UDP-Gal: βGlcNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour,” British Journal of Cancer, vol. 87, no. 9, pp. 1006–1012, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Liu, J. S. Yu, G. Zeng et al., “AIM-2: a novel tumor antigen is expressed and presented by human glioma cells,” Journal of Immunotherapy, vol. 27, no. 3, pp. 220–226, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Wu, J. Xiao, L. Anker et al., “Identification of EGFRvIII-derived CTL epitopes estricted by HLA A0201 for dendritic cell based immunotherapy of gliomas,” Journal of Neuro-Oncology, vol. 76, no. 1, pp. 23–30, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Schmitz, R. Wehner, S. Stevanovic et al., “Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11,” Cancer Letters, vol. 245, no. 1-2, pp. 331–336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. H. T. Khong and S. A. Rosenberg, “Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy,” Journal of Immunology, vol. 168, no. 2, pp. 951–956, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Liu, H. T. Khong, C. J. Wheeler, J. S. Yu, K. L. Black, and H. Ying, “Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma,” Journal of Immunotherapy, vol. 26, no. 4, pp. 301–312, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Ge, N. T. Hoa, A. N. Cornforth et al., “Glioma big potassium channel expression in human cancers and possible T cell epitopes for their immunotherapy,” Journal of Immunology, vol. 189, no. 5, pp. 2625–2634, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. V. Dutoit, C. Herold-Mende, N. Hilf et al., “Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy,” Brain, vol. 135, no. 4, pp. 1042–1054, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. J. H. Sampson, G. E. Archer, D. A. Mitchell, A. B. Heimberger, and D. D. Bigner, “Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma,” Seminars in Immunology, vol. 20, no. 5, pp. 267–275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Renkvist, C. Castelli, P. F. Robbins, and G. Parmiani, “A listing of human tumor antigens recognized by T cells,” Cancer Immunology, Immunotherapy, vol. 50, no. 1, pp. 3–15, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. X. Hu, N. G. Chakraborty, J. R. Sporn, S. H. Kurtzman, M. T. Ergin, and B. Mukherji, “Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine,” Cancer Research, vol. 56, no. 11, pp. 2479–2483, 1996. View at Google Scholar · View at Scopus
  55. M. Marchand, N. van Baren, P. Weynants et al., “Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1,” International Journal of Cancer, vol. 80, no. 2, pp. 219–230, 1999. View at Google Scholar
  56. B. Thurner, I. Haendle, C. Röder et al., “Vaccination with Mage-3A1 peptide-pulsed nature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma,” The Journal of Experimental Medicine, vol. 190, no. 11, pp. 1669–1678, 1999. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Mackensen, B. Herbst, J. Chen et al., “Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells,” International Journal of Cancer, vol. 86, no. 2, pp. 385–392, 2000. View at Google Scholar · View at Scopus
  58. R. M. Prins, S. K. Odesa, and L. M. Liau, “Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model,” Cancer Research, vol. 63, no. 23, pp. 8487–8491, 2003. View at Google Scholar · View at Scopus
  59. S. Phuphanich, C. J. Wheeler, J. D. Rudnick et al., “Phase i trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma,” Cancer Immunology, Immunotherapy: CII, vol. 62, no. 1, pp. 125–135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. J. H. Sampson, A. B. Heimberger, G. E. Archer et al., “Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma,” Journal of Clinical Oncology, vol. 28, no. 31, pp. 4722–4729, 2010. View at Publisher · View at Google Scholar · View at Scopus